Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine

• Verfasst von: Schwerdtfeger, Melanie [VerfasserIn]
• Verfasst von: Andersson, Anne-Marie Carola [VerfasserIn]
• Verfasst von: Neukirch, Lasse [VerfasserIn]
• Verfasst von: Holst, Peter Johannes [VerfasserIn]
• Titel: Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine
• Verf.angabe: Melanie Schwerdtfeger, Anne-Marie Carola Andersson, Lasse Neukirch, Peter Johannes Holst
• E-Jahr: 2019
• Jahr: 24 May 2019
• Umfang: 18 S.
• Fussnoten: Gesehen am 22.07.2019
• Titel Quelle: Enthalten in: Journal of translational medicine
• Ort Quelle: London : BioMed Central, 2003
• Jahr Quelle: 2019
• Band/Heft Quelle: 17(2019), Artikel-ID 175, Seite 1-18
• ISSN Quelle: 1479-5876
• DOI: doi:10.1186/s12967-019-1924-1
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1669553345

Abstract

In non-human primates (NHPs) and humans, partial protection from HIV/SIV infection or suppression of replication is achievable by Env-binding antibodies and Gag-specific CD8+ T-cells targeting protective epitopes. Unfortunately, such T-cell responses are frequently dominated by responses to non-protective, variable epitopes. In this study we attempt to combine three independent approaches, each developed to prevent immunodominance of non-protective epitopes. These approaches were (1) vaccines consisting exclusively of putatively protective p24 Gag highly conserved elements (CEs), (2) vaccines using solely subdominant antigens which were acutely protective in a recent NHP trial, and (3) virus-encoded virus-like particle vaccines (virus-like vaccines/VLVs) using heterologous Env and Gag sequences to enable selection of broadly cross-reactive responses and to avoid immunodominance of non-conserved sequences in prime-boost regimens as previously observed.